Copyright Reports & Markets. All rights reserved.

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 CellSearch
      • 1.4.3 Others
    • 1.5 Market by Application
      • 1.5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Application (2014-2025)
      • 1.5.2 Breast Cancer Diagnosis and Treatment
      • 1.5.3 Prostate Cancer Diagnosis and Treatment
      • 1.5.4 Colorectal Cancer Diagnosis and Treatment
      • 1.5.5 Lung Cancer Diagnosis and Treatment
      • 1.5.6 Other Cancers Diagnosis and Treatment
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size
    • 2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Growth Trends by Regions
      • 2.2.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Regions (2014-2025)
      • 2.2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Manufacturers
      • 3.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Ratio (CR5 and HHI)
    • 3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players Head office and Area Served
    • 3.3 Key Players Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product/Solution/Service
    • 3.4 Date of Enter into Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type (2014-2019)
    • 4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2014-2019)
    • 5.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players in United States
    • 5.3 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
    • 5.4 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application

    6 Europe

    • 6.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2014-2019)
    • 6.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players in Europe
    • 6.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
    • 6.4 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application

    7 China

    • 7.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2014-2019)
    • 7.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players in China
    • 7.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
    • 7.4 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application

    8 Japan

    • 8.1 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2014-2019)
    • 8.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players in Japan
    • 8.3 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
    • 8.4 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2014-2019)
    • 9.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players in Southeast Asia
    • 9.3 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
    • 9.4 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application

    10 India

    • 10.1 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2014-2019)
    • 10.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players in India
    • 10.3 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
    • 10.4 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2014-2019)
    • 11.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players in Central & South America
    • 11.3 Central & South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
    • 11.4 Central & South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application

    12 International Players Profiles

    • 12.1 Janssen
      • 12.1.1 Janssen Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.1.4 Janssen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.1.5 Janssen Recent Development
    • 12.2 Qiagen
      • 12.2.1 Qiagen Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.2.4 Qiagen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.2.5 Qiagen Recent Development
    • 12.3 Advanced Cell Diagnostics
      • 12.3.1 Advanced Cell Diagnostics Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.3.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.3.5 Advanced Cell Diagnostics Recent Development
    • 12.4 ApoCell
      • 12.4.1 ApoCell Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.4.4 ApoCell Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.4.5 ApoCell Recent Development
    • 12.5 Biofluidica
      • 12.5.1 Biofluidica Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.5.4 Biofluidica Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.5.5 Biofluidica Recent Development
    • 12.6 Clearbridge Biomedics
      • 12.6.1 Clearbridge Biomedics Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.6.4 Clearbridge Biomedics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.6.5 Clearbridge Biomedics Recent Development
    • 12.7 CytoTrack
      • 12.7.1 CytoTrack Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.7.4 CytoTrack Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.7.5 CytoTrack Recent Development
    • 12.8 Celsee
      • 12.8.1 Celsee Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.8.4 Celsee Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.8.5 Celsee Recent Development
    • 12.9 Fluxion
      • 12.9.1 Fluxion Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.9.4 Fluxion Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.9.5 Fluxion Recent Development
    • 12.10 Gilupi
      • 12.10.1 Gilupi Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
      • 12.10.4 Gilupi Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2014-2019)
      • 12.10.5 Gilupi Recent Development
    • 12.11 Cynvenio
    • 12.12 On-chip
    • 12.13 YZY Bio
    • 12.14 BioView
    • 12.15 Fluidigm
    • 12.16 Ikonisys
    • 12.17 AdnaGen
    • 12.18 IVDiagnostics
    • 12.19 Miltenyi Biotec
    • 12.20 ScreenCell
    • 12.21 Silicon Biosystems

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

      Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
      According to the research, the most potential market in the main countries of circulating tumor cells (CTCs) and cancer stem cells (CSCs) industry is China, determined by the rising level of medical care. Besides, South America, Asia-Pacific should also be focused by the investors. They are the potential consumers of circulating tumor cells (CTCs) and cancer stem cells (CSCs).
      The CellSearch test is the only FDA-approved test for CTC assessment. For the moment, the products are not comprehensive, and technologies are not stable.
      Morbidity and mortality rate of cancer is rising at a faster speed worldwide and thus prevention of cancer and cancer treatment is grabbing attention of cancer researchers globally. Stem cells and cell therapy have shown significant potential to treat cancer effectively.
      In 2018, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was 6420 million US$ and it is expected to reach 30200 million US$ by the end of 2025, with a CAGR of 21.4% during 2019-2025.

      This report focuses on the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) development in United States, Europe and China.

      The key players covered in this study
      Janssen
      Qiagen
      Advanced Cell Diagnostics
      ApoCell
      Biofluidica
      Clearbridge Biomedics
      CytoTrack
      Celsee
      Fluxion
      Gilupi
      Cynvenio
      On-chip
      YZY Bio
      BioView
      Fluidigm
      Ikonisys
      AdnaGen
      IVDiagnostics
      Miltenyi Biotec
      ScreenCell
      Silicon Biosystems

      Market segment by Type, the product can be split into
      CellSearch
      Others

      Market segment by Application, split into
      Breast Cancer Diagnosis and Treatment
      Prostate Cancer Diagnosis and Treatment
      Colorectal Cancer Diagnosis and Treatment
      Lung Cancer Diagnosis and Treatment
      Other Cancers Diagnosis and Treatment

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) status, future forecast, growth opportunity, key market and key players.
      To present the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now